Research collected over two years shows that drug manufacturing currently wastes $50 billion per year. Among the findings: Manufacturing decisions are often best initiated and implemented by those closest to the work, and companies with strong IT foundations perform better overall.
The study may also have interesting implications for process analytical technologies (PAT), which may influence and change the way that drug manufacturers and regulatory authorities such as the FDA, view the initiative in the future.
Login or register below to access the full 462-page report.